Literature DB >> 1290619

Clinical experience with angiotensin II receptor antagonists.

H R Brunner1, Y Christen, A Munafo, R J Lee, B Waeber, J Nussberger.   

Abstract

This series of studies was designed to assess in normal volunteers the relationships between various doses (5, 10, 20, 40, 80, and 120 mg) of the orally active angiotensin II antagonist losartan (DuP 753, MK-954) and their inhibitory effect on the pressure response to a given bolus of angiotensin I or II. It was found that the maximal inhibitory effect was reached with a dose of 80 mg. The minimal dose necessary for maximal efficacy would therefore be expected to be between 40 and 80 mg. The effect lasted for more than 24 h and was related almost exclusively to the circulating levels of the active metabolite EXP3174. It remains to be demonstrated in hypertensive patients that the same dose relationship holds for the antihypertensive effect, but preliminary data already suggest that this is the case.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1290619     DOI: 10.1093/ajh/5.12.243s

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  6 in total

1.  Evaluation of noninvasive blood pressure recording by photoplethysmography in clinical studies using angiotensin challenges.

Authors:  T Buclin; C Buchwalder-Csajka; H R Brunner; J Biollaz
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

2.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

3.  Receptor occupancy in myocardium, adrenal cortex, and brain by TH-142177, a novel AT1 receptor antagonist in rats, in relation to its plasma concentration and hypotensive effect.

Authors:  Y Nozawa; H Miyake; S Yamada; R Kimura
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

4.  Start of therapy with the angiotensin II antagonist losartan after immediate switch from pretreatment with an ACE inhibitor.

Authors:  J Scholze; M Stapff
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

Review 5.  Pathologic consequences of increased angiotensin II activity.

Authors:  C M Ferrario; J M Flack
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

6.  Apoptosis after reperfused myocardial infarction: Role of angiotensin II.

Authors:  Bodh I Jugdutt
Journal:  Exp Clin Cardiol       Date:  2004
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.